This is a preview of subscription content, log in via an institution to check access.
Reference
Langness J, et al. Simeprevir/Sofosbuvir vs Triple Therapy (Telaprevir or Boceprevir) for HCV GT1: A cost analysis. 22nd Conference on Retroviruses and Opportunistic Infections : abstr. 652, 23 Feb 2015.
Rights and permissions
About this article
Cite this article
Cost per cure similar for new vs older regimens for HCV GT1. PharmacoEcon Outcomes News 725, 9 (2015). https://doi.org/10.1007/s40274-015-2023-z
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-015-2023-z